Guatemala granted humanitarian visas to 161 Mexicans who crossed into that country last week fleeing organized crime.

IGM Biosciences (NASDAQ:IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates, imvotamab and IGM-2644, in the wake of disappointing data.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% ...

A high-level overview of IGM Financial Inc. (IGIFF) stock. View (IGIFF) real-time stock price, chart, news, analysis, analyst reviews and more.

Mary Beth Harler, M.D., a Bristol Myers Squibb veteran who joined IGM in 2021 to head up the biotech's autoimmune R&D, will step into the CEO role. “Our early pivot to using T cell engagers in ...

IGM earned a buy rating with a quant score of 4.16, according to the Seeking Alpha quant system. It received an A grade on a momentum factor and a negative B on its expense ratio of 0.41%.

CNW/ - (IGM or the Company) (TSX: IGM) today announced earnings results for the second quarter of 2025. IGM HIGHLIGHTS Record high ...

A hepatitis A immunoglobulin G (IgG)-positive and immunoglobulin M (IgM)-negative test result may indicate immunity to hepatitis A. Learn more here.

IGM Financial Inc., a Canadian asset manager controlled by Quebec’s Desmarais family, will take a C$76 million ($57.3 million) restructuring charge as it cuts jobs and reduces costs.